Company intelligence / Profile preview

N-of-One

Concord, Massachusetts, United Statesnofone.org ↗

Ownership: Private
Development stage: Commercial

Overview

N-of-One provided molecular decision support services to clinicians by interpreting complex genomic test results for cancer patients. Their proprietary technology enabled personalized treatment recommendations based on each patient’s unique molecular profile. The company supported tens of thousands of cases prior to its acquisition by QIAGEN in January 2019.

Therapeutic areas: Oncology
Industry: Digital Health Medical Devices

Partnerships

Worked with hospital systems, cancer centers, commercial labs; now part of QIAGEN’s broader partnership network post-acquisition.

Beyond the preview

Go deeper on N-of-One.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-of-One.

Explore the full profile